Darunavir contraindications: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
 
Line 6: Line 6:


Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on [[CYP3A]] for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). These drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed in Table 6.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PREZISTA (DARUNAVIR) TABLET, FILM COATED PREZISTA (DARUNAVIR) SUSPENSION [JANSSEN PRODUCTS LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=814301f9-c990-46a5-b481-2879a521a16f#nlm34090-1 | publisher =  | date =  | accessdate =  }}</ref>
Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on [[CYP3A]] for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). These drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed in Table 6.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PREZISTA (DARUNAVIR) TABLET, FILM COATED PREZISTA (DARUNAVIR) SUSPENSION [JANSSEN PRODUCTS LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=814301f9-c990-46a5-b481-2879a521a16f#nlm34090-1 | publisher =  | date =  | accessdate =  }}</ref>


{|
{|

Latest revision as of 23:52, 31 December 2013

Darunavir
PREZISTA® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Contraindications

Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). These drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed in Table 6.[1]

References

  1. "PREZISTA (DARUNAVIR) TABLET, FILM COATED PREZISTA (DARUNAVIR) SUSPENSION [JANSSEN PRODUCTS LP]".

Adapted from the FDA Package Insert.